Inter- and intra-observational variability in immunohistochemistry: a multicentre analysis of diffuse large B-cell lymphoma staining

1 Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Childrens Oncology Group phase 1 consortium study The Lancet Oncology, April 24, 2013

2 Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma Journal of Clinical Oncology, May 9, 2013

3 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013

4 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet, April 23, 2013

5 Japonicone a suppresses growth of Burkitt lymphoma cells through its effect on NF-kappaB Clinical Cancer Research, May 15, 2013

6 Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study The Lancet Oncology, May 3, 2013

7 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013

8 The epidemic of non-Hodgkin lymphoma in the United States: Disentangling the effect of HIV, 1992-2009 Cancer Epidemiology, Biomarkers & Prevention, April 25, 2013

9 Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancer-free, HIV-1-infected patients Cancer, April 29, 2013

10 Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network Annals of Oncology, April 29, 2013    Review Article